Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ischemic Heart Disease

  Free Subscription

Articles published in
Lancet
    May 2018
  1. BRILAKIS ES, Edson R, Bhatt DL, Goldman S, et al
    Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial.
    Lancet. 2018 May 11. pii: S0140-6736(18)30801.
    >> Share

  2. PYLYPCHUK R, Wells S, Kerr A, Poppe K, et al
    Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study.
    Lancet. 2018 May 4. pii: S0140-6736(18)30664.
    >> Share

  3. DAMEN JAAG, Hooft L, Moons KGM
    Contemporary cardiovascular risk prediction.
    Lancet. 2018 May 4. pii: S0140-6736(18)30842.
    >> Share

    April 2018
  4. DEHGHAN M, Mente A, Yusuf S
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple? - Authors' reply.
    Lancet. 2018;391:1681-1682.
    >> Share

  5. HANSEL B, Roussel R, Giral P
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1680.
    >> Share

  6. KLEBER ME, Delgado GE, Dawczynski C, Lorkowski S, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1680-1681.
    >> Share

  7. CAO XP, Tan CC, Yu JT
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1679-1680.
    >> Share

  8. CARBONE S, Billingsley H, Abbate A
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1679.
    >> Share

  9. LORKOWSKI S, Richter M, Linseisen J, Watzl B, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1678-1679.
    >> Share

  10. ROSSOUW JE, Prentice RL
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1677.
    >> Share

  11. BHOPAL RS, Misra A
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1677-1678.
    >> Share

  12. MANN J, Meerpohl J, Nishida C, McLean R, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1676.
    >> Share

  13. REYNOLDS AN
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1676.
    >> Share

  14. KAHLEOVA H, Crosby L, Levin S, Barnard ND, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1676-1677.
    >> Share

    March 2018
  15. ALKHALIL M
    Bioresorbable polymer drug-eluting stents.
    Lancet. 2018;391:936.
    >> Share

  16. KANDZARI DE, Mauri L, Koolen JJ, Doros G, et al
    Bioresorbable polymer drug-eluting stents - Authors' reply.
    Lancet. 2018;391:936-937.
    >> Share

  17. SHAH R
    Bioresorbable polymer drug-eluting stents.
    Lancet. 2018;391:935-936.
    >> Share

  18. MOTOVSKA Z, Bhatt DL
    12 months of DAPT after acute coronary syndrome still beats 6 months.
    Lancet. 2018 Mar 9. pii: S0140-6736(18)30612.
    >> Share

  19. HAHN JY, Song YB, Oh JH, Cho DK, et al
    6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
    Lancet. 2018 Mar 9. pii: S0140-6736(18)30493.
    >> Share

    February 2018
  20. HEAD SJ, Milojevic M, Daemen J, Ahn JM, et al
    Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data.
    Lancet. 2018 Feb 22. pii: S0140-6736(18)30423.
    >> Share

  21. PAULES CI, Subbarao K
    Influenza vaccination and prevention of cardiovascular disease mortality - Authors' reply.
    Lancet. 2018;391:427-428.
    >> Share

  22. CALDEIRA D, Ferreira JJ, Costa J
    Influenza vaccination and prevention of cardiovascular disease mortality.
    Lancet. 2018;391:426-427.
    >> Share

    January 2018
  23. JOBS A, Desch S, Thiele H
    Great expectations - Authors' reply.
    Lancet. 2018;391:306-307.
    >> Share

  24. LEMESLE G, Laine M, Pankert M, Puymirat E, et al
    Great expectations.
    Lancet. 2018;391:306.
    >> Share

  25. BOCHATON T, Ovize M
    Circadian rhythm and ischaemia-reperfusion injury.
    Lancet. 2018;391:8-9.
    >> Share

  26. BROWN DL, Redberg RF
    Last nail in the coffin for PCI in stable angina?
    Lancet. 2018;391:3-4.
    >> Share

  27. GERBER RT, Gershlick AH
    A SENIOR moment? Bare-metal stents in elderly patients.
    Lancet. 2018;391:4-6.
    >> Share

    December 2017
  28. SCHUMACHER H, Mahfoud F, Bohm M
    Overestimation of cardiovascular outcome incidence - Authors' reply.
    Lancet. 2017;390:2547.
    >> Share

  29. YE Y, Fonseca R
    Overestimation of cardiovascular outcome incidence.
    Lancet. 2017;390:2546-2547.
    >> Share

  30. THURSTON GD, Newman JD
    Walking to a pathway for cardiovascular effects of air pollution.
    Lancet. 2017 Dec 5. pii: S0140-6736(17)33078.
    >> Share

  31. SINHARAY R, Gong J, Barratt B, Ohman-Strickland P, et al
    Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants aged 60 years and older with chronic lung or heart disease and age-matched healthy controls: a randomised, cr
    Lancet. 2017 Dec 5. pii: S0140-6736(17)32643.
    >> Share

  32. DE WINTER RJ, Katagiri Y, Asano T, Milewski KP, et al
    A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 tri
    Lancet. 2017 Dec 1. pii: S0140-6736(17)33103.
    >> Share

    November 2017
  33. RIDKER PM, MacFadyen JG, Everett BM, Libby P, et al
    Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
    Lancet. 2017 Nov 13. pii: S0140-6736(17)32814.
    >> Share

  34. CONNOLLY SJ, Eikelboom JW, Bosch J, Dagenais G, et al
    Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Lancet. 2017 Nov 10. pii: S0140-6736(17)32458.
    >> Share

  35. PRABHAKARAN D, Anand S, Watkins D, Gaziano T, et al
    Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition.
    Lancet. 2017 Nov 3. pii: S0140-6736(17)32471.
    >> Share

  36. AL-LAMEE R, Thompson D, Dehbi HM, Sen S, et al
    Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.
    Lancet. 2017 Nov 1. pii: S0140-6736(17)32714.
    >> Share

    October 2017
  37. VARENNE O, Cook S, Sideris G, Kedev S, et al
    Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial.
    Lancet. 2017 Oct 31. pii: S0140-6736(17)32713.
    >> Share

  38. MONTAIGNE D, Marechal X, Modine T, Coisne A, et al
    Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbalpha antagonism: a single-centre propensity-matched cohort study and a randomised study.
    Lancet. 2017 Oct 26. pii: S0140-6736(17)32132.
    >> Share

  39. BYRNE RA, Schuster T
    Biodegradable polymer drug-eluting stents: caveat emptor.
    Lancet. 2017;390:1814-1816.
    >> Share

    September 2017
  40. LEAR SA, Hu W, Rangarajan S, Gasevic D, et al
    The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study.
    Lancet. 2017 Sep 21. pii: S0140-6736(17)31634.
    >> Share

    August 2017
  41. DEHGHAN M, Mente A, Zhang X, Swaminathan S, et al
    Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study.
    Lancet. 2017 Aug 28. pii: S0140-6736(17)32252.
    >> Share

  42. MILLER V, Mente A, Dehghan M, Rangarajan S, et al
    Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study.
    Lancet. 2017 Aug 28. pii: S0140-6736(17)32253.
    >> Share

  43. SIBBING D, Aradi D, Jacobshagen C, Gross L, et al
    Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32155.
    >> Share

  44. KANDZARI DE, Mauri L, Koolen JJ, Massaro JM, et al
    Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32249.
    >> Share

  45. JINATONGTHAI P, Kongwatcharapong J, Foo CY, Phrommintikul A, et al
    Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis.
    Lancet. 2017;390:747-759.
    >> Share

  46. CUISSET T, Verheugt FWA, Mauri L
    Update on antithrombotic therapy after percutaneous coronary revascularisation.
    Lancet. 2017;390:810-820.
    >> Share

  47. MINTZ GS, Guagliumi G
    Intravascular imaging in coronary artery disease.
    Lancet. 2017;390:793-809.
    >> Share

  48. THE LANCET
    40 years of percutaneous coronary intervention: where next?
    Lancet. 2017;390:715.
    >> Share

  49. DAMMAN P, de Winter RJ
    Timing of revascularisation for acute coronary syndrome.
    Lancet. 2017 Aug 1. pii: S0140-6736(17)31632.
    >> Share

  50. JOBS A, Mehta SR, Montalescot G, Vicaut E, et al
    Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials.
    Lancet. 2017 Aug 1. pii: S0140-6736(17)31490.
    >> Share

    July 2017
  51. ALI ZA, Serruys PW, Kimura T, Gao R, et al
    2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.
    Lancet. 2017 Jul 18. pii: S0140-6736(17)31470.
    >> Share

    May 2017
  52. RUTTY GN, Morgan B, Robinson C, Raj V, et al
    Diagnostic accuracy of post-mortem CT with targeted coronary angiography versus autopsy for coroner-requested post-mortem investigations: a prospective, masked, comparison study.
    Lancet. 2017 May 24. pii: S0140-6736(17)30333.
    >> Share

    April 2017
  53. KOOPMAN JJE, Kuipers RS
    From arterial ageing to cardiovascular disease.
    Lancet. 2017;389:1676-1678.
    >> Share

  54. SHAH R
    Optical coherence tomography-guided PCI.
    Lancet. 2017;389:1607.
    >> Share

  55. KAHAN T
    Target blood pressure in patients at high cardiovascular risk.
    Lancet. 2017 Apr 5. pii: S0140-6736(17)30935.
    >> Share

  56. BOHM M, Schumacher H, Teo KK, Lonn EM, et al
    Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    Lancet. 2017 Apr 5. pii: S0140-6736(17)30754.
    >> Share

  57. VIDAL-PETIOT E, Bhatt DL, Fox KM, Steg PG, et al
    Blood pressure and cardiovascular outcomes: a closer look - Authors' reply.
    Lancet. 2017;389:1296-1297.
    >> Share

  58. WALD NJ, Wald DS
    Blood pressure and cardiovascular outcomes: a closer look.
    Lancet. 2017;389:1296.
    >> Share

  59. DOUMAS M, Stavropoulos KV, Boutari C, Imprialos KP, et al
    Blood pressure and cardiovascular outcomes: a closer look.
    Lancet. 2017;389:1295-1296.
    >> Share

    March 2017
  60. SCHOOLING CM
    Tachykinin neurokinin 3 receptor antagonists: a new treatment for cardiovascular disease?
    Lancet. 2017 Mar 27. pii: S0140-6736(16)31648.
    >> Share

  61. GURBEL PA, Tantry US
    GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes.
    Lancet. 2017 Mar 17. pii: S0140-6736(17)30760.
    >> Share

  62. OHMAN EM, Roe MT, Steg PG, James SK, et al
    Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Lancet. 2017 Mar 17. pii: S0140-6736(17)30751.
    >> Share

  63. KAPLAN H, Thompson RC, Trumble BC, Wann LS, et al
    Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study.
    Lancet. 2017 Mar 16. pii: S0140-6736(17)30752.
    >> Share

  64. THE LANCET
    Polypills: an essential medicine for cardiovascular disease.
    Lancet. 2017;389:984.
    >> Share

  65. HUFFMAN MD, Xavier D, Perel P
    Uses of polypills for cardiovascular disease and evidence to date.
    Lancet. 2017;389:1055-1065.
    >> Share

    January 2017
  66. BLACHER J, Levy BI, Mourad JJ, Safar ME, et al
    Hypertension control and cardiovascular disease - Authors' reply.
    Lancet. 2017;389:154-155.
    >> Share

  67. JAMES JE
    Hypertension control and cardiovascular disease.
    Lancet. 2017;389:154.
    >> Share

  68. MESSERLI FH, Fischer U, Rimoldi SF, Bangalore S, et al
    Hypertension control and cardiovascular disease.
    Lancet. 2017;389:153.
    >> Share

  69. TAWAKOL A, Ishai A, Takx RA, Figueroa AL, et al
    Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study.
    Lancet. 2017 Jan 12. pii: S0140-6736(16)31714.
    >> Share

    November 2016
  70. COLLINS R, Reith C, Emberson J, Armitage J, et al
    Interpretation of the evidence for the efficacy and safety of statin therapy.
    Lancet. 2016;388:2532-2561.
    >> Share

    October 2016
  71. MAKIKALLIO T, Holm NR, Lindsay M, Spence MS, et al
    Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32052.
    >> Share

  72. MACK M, Holmes DR
    Randomised trials in left main disease: a NOBLE effort.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32067.
    >> Share

  73. VON BIRGELEN C, Kok MM, van der Heijden LC, Danse PW, et al
    Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)31920.
    >> Share

  74. FINN AV, Virmani R
    Biodegradable polymer drug-eluting stents: non-inferiority waiting for superiority?
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32063.
    >> Share

  75. ALI ZA, Maehara A, Genereux P, Shlofmitz RA, et al
    Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)31922.
    >> Share

  76. SERRUYS PW, Chevalier B, Sotomi Y, Cequier A, et al
    Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32050.
    >> Share

  77. ROSSIGNOL P, Pitt B, Thompson A, Zannad F, et al
    Roadmap for cardiovascular prevention trials in chronic kidney disease.
    Lancet. 2016;388:1964-1966.
    >> Share

  78. GUAN WJ, Zheng XY, Chung KF, Zhong NS, et al
    Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action.
    Lancet. 2016;388:1939-1951.
    >> Share

  79. ISAAZ K, Gerbay A
    Deferred stenting in acute ST elevation myocardial infarction.
    Lancet. 2016;388:1371.
    >> Share

  80. KELBAEK H, Hofsten DE, Engstrom T, Helqvist S, et al
    Deferred stenting in acute ST elevation myocardial infarction - Authors' reply.
    Lancet. 2016;388:1371-1372.
    >> Share

  81. WONG EM, Chair SY, Leung DY, Sit JW, et al
    The effect of an e-health web-based support programme on psychological outcomes and health related quality of life among Chinese patients with coronary heart disease: a parallel-group randomised controlled trial.
    Lancet. 2016;388 Suppl 1:S86.
    >> Share

    September 2016
  82. FEINBERG MW
    No small task: therapeutic targeting of Lp(a) for cardiovascular disease.
    Lancet. 2016 Sep 21. pii: S0140-6736(16)31329.
    >> Share

    August 2016
  83. CAYLA G, Cuisset T, Silvain J, Leclercq F, et al
    Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial.
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31323.
    >> Share

  84. VIDAL-PETIOT E, Ford I, Greenlaw N, Ferrari R, et al
    Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study.
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31326.
    >> Share

  85. MANCIA G
    Should blood pressure reduction be aggressive in patients with hypertension and coronary artery disease?
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31398.
    >> Share

  86. WEINTRAUB WS
    Invasive management of acute coronary syndromes.
    Lancet. 2016 Aug 25. pii: S0140-6736(16)31273.
    >> Share

  87. WALLENTIN L, Lindhagen L, Arnstrom E, Husted S, et al
    Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study.
    Lancet. 2016 Aug 25. pii: S0140-6736(16)31276.
    >> Share

  88. REED GW, Rossi JE, Cannon CP
    Acute myocardial infarction.
    Lancet. 2016 Aug 5. pii: S0140-6736(16)30677.
    >> Share

    July 2016
  89. SNYDER A
    Philip Majerus.
    Lancet. 2016;388:458.
    >> Share

  90. KAIN K
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:126.
    >> Share

  91. ETTEHAD D, Emdin CA, Kiran A, Rahimi K, et al
    Blood pressure lowering for cardiovascular disease - Authors' reply.
    Lancet. 2016;388:126-7.
    >> Share

  92. O'KEEFFE DT, Maraka S
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125.
    >> Share

  93. SMULDERS YM, Muller M
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125-6.
    >> Share

  94. COLLINS DR, Albasri A, O'Sullivan J, Bobrovitz N, et al
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125.
    >> Share

  95. STONE GW, Gao R, Kimura T, Simonton C, et al
    Optimum technique to reduce risk of stent thrombosis - Authors' reply.
    Lancet. 2016;388:127-8.
    >> Share

  96. SHAH R
    Optimum technique to reduce risk of stent thrombosis.
    Lancet. 2016;388:127.
    >> Share

    June 2016
  97. GLADWIN MT
    Cardiovascular complications and risk of death in sickle-cell disease.
    Lancet. 2016;387:2565-74.
    >> Share

  98. TEGN N, Abdelnoor M, Aaberge L, Endresen K, et al
    Invasive strategy in acute coronary syndrome - Authors' reply.
    Lancet. 2016;387:2504.
    >> Share

  99. MATHEW ST, Pakala AV, Thadani U
    Invasive strategy in acute coronary syndrome.
    Lancet. 2016;387:2503-4.
    >> Share

  100. SHAH R
    Invasive strategy in acute coronary syndrome.
    Lancet. 2016;387:2503.
    >> Share

  101. TIMMIS A
    Invasive strategy in acute coronary syndrome.
    Lancet. 2016;387:2503.
    >> Share

  102. POVSIC TJ, Zeiher AM
    IxCELL-DCM: rejuvenation for cardiac regenerative therapy?
    Lancet. 2016;387:2362-3.
    >> Share

  103. FUJITA T
    Measurement of cardiac troponin for exclusion of myocardial infarction.
    Lancet. 2016;387:2289.
    >> Share

  104. FORD C, Whitehead SJ, Gama R, Willmer KA, et al
    Measurement of cardiac troponin for exclusion of myocardial infarction.
    Lancet. 2016;387:2289.
    >> Share

  105. SHAH AS, Anand A, Chapman AR, Newby DE, et al
    Measurement of cardiac troponin for exclusion of myocardial infarction - Authors' reply.
    Lancet. 2016;387:2289-91.
    >> Share

  106. BOEDDINGHAUS J, Twerenbold R, Nestelberger T, Wildi K, et al
    Measurement of cardiac troponin for exclusion of myocardial infarction.
    Lancet. 2016;387:2288.
    >> Share

  107. MULLEN L, Chew PG, Frost F, Obafemi T, et al
    Measurement of cardiac troponin for exclusion of myocardial infarction.
    Lancet. 2016;387:2288-9.
    >> Share

  108. DALE A, Slade E, Heneghan C
    Outcomes reporting of the FAME trial.
    Lancet. 2016;387:2292.
    >> Share

    May 2016
  109. LAFONT A, Mennuni MG
    Effect on death of scaffold thrombosis versus stent thrombosis.
    Lancet. 2016;387:2198.
    >> Share

  110. KAUFMAN JD, Adar SD, Barr RG, Budoff M, et al
    Association between air pollution and coronary artery calcification within six metropolitan areas in the USA (the Multi-Ethnic Study of Atherosclerosis and Air Pollution): a longitudinal cohort study.
    Lancet. 2016 May 24. pii: S0140-6736(16)00378.
    >> Share

  111. MENTE A, O'Donnell M, Rangarajan S, Dagenais G, et al
    Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies.
    Lancet. 2016 May 20. pii: S0140-6736(16)30467.
    >> Share

  112. SABATE M, Brugaletta S
    Outcomes in the EXAMINATION trial - Authors' reply.
    Lancet. 2016;387:1998.
    >> Share

  113. DRYSDALE H, Hartley P, Goldacre B
    Outcomes in the EXAMINATION trial.
    Lancet. 2016;387:1997-8.
    >> Share

  114. CASSESE S, Kastrati A
    Risk of stent thrombosis with bioresorbable vascular scaffolds - Authors' reply.
    Lancet. 2016;387:1904.
    >> Share

  115. SHAH R, Ramos-Bondy B, Mizeracki A
    Risk of stent thrombosis with bioresorbable vascular scaffolds.
    Lancet. 2016;387:1903.
    >> Share

    April 2016
  116. VESTBO J, Anderson JA, Brook RD, Calverley PM, et al
    Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
    Lancet. 2016;387:1817-1826.
    >> Share

  117. VAN 'T HOF AW, Ottervanger JP
    Primary angioplasty for STEMI: hard to improve upon.
    Lancet. 2016 Apr 1. pii: S0140-6736(16)30123.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016